Resident Journal Club |HDR monotherapy vs SBRT for intermediate risk prostate cancer
May 14, 2026 |12:00 PM ET
Prostate cancer treatment is shifting toward ultra-hypofractionation. But which is superior: the procedural precision of HDR Monotherapy or the non-invasive efficiency of SBRT?
Join the ABS Resident Prostate Journal Club for an evidence-based breakdown of the latest 10-year prospective data. We will compare long-term biochemical control rates, analyze acute vs. late toxicities, and discuss the "vanishing art" of brachytherapy in the modern era of hypofractionated radiation.
Faculty:
Daniela Martir-Vargas, MD, University of Florida
Ahmed Nawwar, MD, University of Kansas Medical Center
Sarthak Shah, MD, Rutgers Cancer Institute
Moderator:
Jay Shiao, MD University of Kansas Medical Center